Coordinated defence and the liver.
The liver is strategically placed to protect the body against a vast array of potentially harmful compounds. The steps involved include phase I metabolism which makes molecules more reactive and phase II reactions which generally enhance solubility in bile or urine. Recent discoveries have shown how regulation of these reactions is also closely allied to expression of membrane transporters which excrete the products of biotransformation into bile and prevent their reabsorption via the intestine. The coordinated activity of these various functions is orchestrated by orphan nuclear receptors which, in response to an encounter with a potential toxin, are able to induce expression of the genes involved in its biotransformation and excretion. Lithocholic acid (LCA) is routinely produced in our intestine by bacterial deconjugation of chenodeoxycholic acid a major bile acid in humans. In human liver the presence of LCA is sensed by the pregnane X receptor (PXR) which has the potential to switch on all the genes required for safe metabolism and elimination of LCA from the body. These include cytochrome P450 3A which hydroxylates LCA to more soluble forms and sulfotransferase (SULT2A1) which by sulphation of LCA makes it more readily solublein bile and enhances its faecal excretion. Similarly, PXR exposure to LCA produces up-regulated expression of the membrane transporters MDR1 and MRP2 which excrete metabolites of LCA. Evidence is accumulating in support of the hypothesis that deficiencies in these defence mechanisms underlie susceptibility to primary sclerosing cholangitis and ulcerative colitis.
Elias
Elwyn
E
Liver Unit, Queen Elizabeth Hospital, Birmingham. Elwyn.Elias@uhb.nhs.uk
Mills
Charles O
CO
D001647:Bile Acids and Salts / Q000502:physiology*; D001692:Biological Transport / Q000502:physiology; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology*; D004198:Disease Susceptibility; D004790:Enzyme Induction / Q000502:physiology; D005767:Gastrointestinal Diseases / Q000503:physiopathology*; D006801:Humans; D008095:Lithocholic Acid / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000502:physiology*; D008107:Liver Diseases / Q000503:physiopathology*; D004364:Pharmaceutical Preparations / Q000378:metabolism; D000077297:Pregnane X Receptor; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D011987:Receptors, Steroid / Q000502:physiology; D015262:Xenobiotics / Q000378:metabolism
D001647:Bile Acids and Salts; D004364:Pharmaceutical Preparations; D000077297:Pregnane X Receptor; D018160:Receptors, Cytoplasmic and Nuclear; D011987:Receptors, Steroid; D015262:Xenobiotics; D008095:Lithocholic Acid; D003577:Cytochrome P-450 Enzyme System